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Marked T cell activation, senescence, exhaustion
and skewing towards TH17 in patients with
COVID-19 pneumonia
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The immune system of patients infected by SARS-CoV-2 is severely impaired. Detailed
investigation of T cells and cytokine production in patients affected by COVID-19 pneumonia
are urgently required. Here we show that, compared with healthy controls, COVID-19
patients’ T cell compartment displays several alterations involving naïve, central memory,
effector memory and terminally differentiated cells, as well as regulatory T cells and PD1
+CD57+ exhausted T cells. Significant alterations exist also in several lineage-specifying
transcription factors and chemokine receptors. Terminally differentiated T cells from patients
proliferate less than those from healthy controls, whereas their mitochondria functionality is
similar in CD4+ T cells from both groups. Patients display significant increases of proin-
flammatory or anti-inflammatory cytokines, including T helper type-1 and type-2 cytokines,
chemokines and galectins; their lymphocytes produce more tumor necrosis factor (TNF),
interferon-γ, interleukin (IL)-2 and IL-17, with the last observation implying that blocking IL-17
could provide a novel therapeutic strategy for COVID-19.
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The dramatic pandemic caused by the severe acuterespiratory syndrome coronavirus (SARS-CoV-2) thatcauses Corona Virus Disease-2019 (COVID-19)1, is a
dramatic threat to our species that is changing daily habits and
social behaviors all over the world. In Italy, the first patients with
severe pneumonia of unknown origin were observed in Lom-
bardy, first confirmed case dating to February 21st, 20202. From
that moment, we saw an unpredictable number of patients with
severe pneumonia, whose treatment often required admission
into intensive care units. Unfortunately, many patients failed in
their fight against the virus, and, as of June 18th, Italy has counted
more than 35,000 deaths amongst over 240,000 infections.
The pathophysiology of such virus is not yet completely
understood3,4. Previous studies on severe diseases caused by other
coronaviruses indicated that pulmonary inflammation is asso-
ciated with increased plasma levels of proinflammatory
cytokines5,6. A similar phenomenon has been described in
patients with COVID-19, who can experience the so-called
“cytokine storm7”. However, little is known about the cells that
are involved in the production of these mediators or about the
specific immune response of patients with COVID-19.
Currently, we, and others, are observing that COVID-19 is
much more severe in elderly patients, especially in those with
different comorbidities, diabetes, and obesity, while it appears
much less severe in children and pregnant women8–10. Immu-
nological aging is associated with a chronic, subclinical inflam-
matory state, defined “inflammaging” where T helper (TH) type 1
lymphocytes play a crucial role, whereas children and pregnant
women have a tendency to develop TH2 responses, so producing
less proinflammatory molecules11,12. In order to better under-
stand how immune response and cytokine production are
orchestrated, we have deeply characterized T cells, and have
studied the functional differentiation of T cells towards TH1,
TH2, or TH17. For this purpose, we have employed an array of
flow cytometric approaches combined with sophisticated tech-
niques for unsupervised analysis of complex T cell phenotypes,
and we have investigated the proliferative capability of different
CD4+ and CD8+ T cell subsets, along with mitochondria func-
tionality in CD4+ T cells. We have finally measured plasma levels
of 31 cytokines and the polyfunctionality of T cells.
A retrospective study performed by our group evidenced that a
drug able to block the biological activities of IL-6, such as toci-
lizumab, can significantly reduce invasive mechanical ventilation
or death in severe COVID-19 pneumonia (defined as the con-
comitant presence of a respiratory rate ≥30 breaths per minute,
blood oxygen saturation ≤93%, a PaO2/FiO2 ratio <300 mmHg in
room air and lung infiltrates >50% of the lung, filed within 24–48
h)13. Even if our results need to be confirmed by randomized
trials, it is to note that, in comparison with the control group,
COVID-19 patients treated with tocilizumab had an increased
prevalence of severe infection.
Here we show that COVID-19 patients have reduction in
absolute numbers of CD4+ and CD8+ T lymphocytes, which
display markers related to activation or exhaustion/senescence,
along with altered expression of master regulators and of several
chemokine receptors. Meanwhile, their CD4+ T cells have an
altered cell proliferation but not mitochondria functionality,
measured as mitochondrial oxygen consumption and extra-
cellular acidification rate (ECAR). In these patients, a massive
cytokine storm detectable in plasma is accompanied by an
increased in vitro production of tumor necrosis factor (TNF),
interferon (IFN)-γ, interleukin (IL)-2, as well as by a skewing
toward the TH17 or Tc17 phenotype. This not only underlines
the efficacy of a drug that contrasts cytokine storm, but also
suggests the clinical evaluation of novel strategies, based upon the
inhibition of the IL-17 pathway.
Results
Characteristics of the patients. We have studied a total of 39
patients, the first 21 of which were consecutively admitted into
the Infectious Diseases Clinics of the University Hospital in
Modena over the period of March 12th–March 30th, 2020,
whereas the remaining patients were studied between April 15th
and May 10th. All patients had symptoms including sore throat,
fever, cough, dyspnoea, and chest pain. At admission, SARS-
CoV-2 was detected in a nasopharyngeal swab specimen by real-
time reverse-transcriptase PCR, and in all of them pneumonia
was subsequently confirmed by X-ray. Supplementary Tables 1–4
show in details the individual clinical and biohumoral char-
acteristics of the patients. Note that, in general, they were lym-
phopenic (mean: 1150 cells/μL, range: 360–2334), and in some
cases lymphocyte count was very low. For the immunological
analyses described below, they were compared with a total of 25
age- and sex-matched healthy controls. For those controls in
which we investigated T cell phenotypes, we could measure the
lymphocyte absolute number, whose mean was 2320 cells/μL,
range: 1580–3130 (controls vs. patients: p < 0.0001).
Characterization and count of CD4+ T cell subsets. We studied
CD4+ and CD8+ T cells in patients and controls using 18 para-
meter flow cytometry. The analysis of the data was then per-
formed by using two complementary methodologies. In the first,
we used the classical approach based upon the two-dimensional
recognition of a given cell type, followed by a first gate that was
required to identify the population of interest (i.e., CD4+ or
CD8+ lymphocytes), followed by sequential gates to identify
markers of activation, differentiation, senescence, exhaustion,
regulatory CD4+ T cells, and memory stem T cells (TSCM). Data
obtained with this gating strategy were then analyzed by appro-
priate, non-parametric statistical tests, and represented in the
figures as scatter plots with means and standard errors of the
mean. In the second, we performed an unsupervised analysis that
considers the entire, complex scenario presented by CD4+ or
CD8+ T cells. This analytical technique uses the multi-
dimensional information obtained by FlowSOM meta-clustering
coupled to a dimension-reduction method such as the Uniform
Manifold Approximation and Projection (UMAP). Heat maps
finally report statistical analysis (see Methods for details). The
same approach was used to study CD8+ T lymphocytes.
Figure 1a shows the aforementioned gating strategy that we used
to compare CD4+ T cells of healthy donors and COVID-19
patients. A first gate was set on the parameters “time” and
“viability”, then a second gate was set on CD3+CD45+ cells (i.e., T
lymphocytes), among which we identified CD4+ or CD8+
lymphocytes. Within the CD4+ population, we analyzed markers
commonly related to T cell activation (HLA-DR and CD38),
senescence and exhaustion (CD57 and PD1), differentiation
(CD45RA, CCR7, CD28, and CD27), regulatory T cells (Treg,
considered as CD25high and CD127low), among which we could
identify diverse differentiation stages, and finally TSCM (i.e., CD95+
cells within CD45RA+CCR7+CD27+CD28+ naïve lymphocytes).
Figure 1b shows that patients had a similar percentage of
CD4+ T cells to controls, but the absolute number of these cells
was significantly lower. A similar phenomenon was observed as
far as naïve, central memory, and effector memory CD4+ T cells
were concerned, whereas the percentage but not the absolute
number of terminally differentiated (TE) cells was higher in
patients. Figure 1c reports that patients also expressed higher
percentages, but not absolute numbers, of activated cells (co-
expressing HLA-DR and CD38), of senescent/exhausted cells
(PD1+CD57+) and of regulatory T cells (Treg).
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We then used a more sophisticated approach to detect fine
changes occurring within different subpopulations of CD4+
T cells. For each patient and control, data from 5000 CD45+
CD3+CD4+ T cells were exported and concatenated in a unique
matrix. We explored the T helper cell panel by unsupervised
analysis using FlowSOM14; this performs multivariate clustering
of cells based on the self-organized map (defined “SOM”)
algorithm, categorizing cells into relevant meta-clusters based
on their surface markers. We first clustered all individual
cells into 25 distinct clusters based on the surface expression
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marker proteins. Then, to reduce complexity, we merged
the clusters that were very close each other and further re-
clustered cells into 15 meta-clusters representing different T
cell types on the basis of activation, differentiation, and
exhaustion. Doing so, we used a dimensionality reduction method,
the “UMAP” to distinguish several CD4+ T cell populations
(Fig. 2a), whose percentages are reported in the heat map shown
in Fig. 2b. It is possible to immediately recognize the high amount
of naïve T cells (red dots), that were CD45RA+ CD28+CCR7+
CD27+CD127+CD25+CD95−CD38−HLA-DR− 15, and that were
similar between the two groups; then, we identified recently
activated naïve T cells expressing CD38, and those expressing HLA-
DR. We also found a small percentage of T cells representing CD4+
memory stem cells characterized by the expression of CD95 and
CD3816, that was similar across the two groups.
Central memory T cells are characterized by expression of
CD45RA, CD28, CD27, CD127, and CD95 molecules. Within
these, a population expressing only CD38 has been identified, and
a population of cells that were activated (HLA-DR+CD38+) and
also expressed PD1. In patients, these two populations were
significantly more frequent than in controls.
Regarding the effector memory compartment, part of the
transitional effector memory T cells are characterized by the lack
of expression of CD45RA and CCR7, but express CD28. Effector
memory cells were characterized by the lack of expression of
CD45RA, CCR7, CD27, CD28, CD38, and HLA-DR and mid
expression of PD1, CD127, and CD25; in addition, effector
memory expressing marker related to exhaustion (like PD1) were
significantly higher in the patients’ group. Terminally effector
memory T cells that express CD45RA, CD25, CD127, and CD95
did not differ between the two groups, as well as TSCM.
Finally, we are well aware that T regulatory cells (Treg) can be
better identified by the expression of Foxp3, which is not present in
our panel. However, thanks to the expression of CD127 (low) and
CD25 (high), we were able to identify three different putative
populations of T regulatory cells: those naïve (expressing CD45RA+
CCR7+), central memory (CD45RA−CCR7+) and the most
represented subset of effector memory (CD45RA−CCR7−). The
comparison of different clusters between healthy donors and
COVID-19 patients is shown in Fig. 2c. It is to note that patients
were characterized by higher percentage of naïve Treg cells (p value
was lower than the lower limit of the statistical analysis provided the
software, i.e., <10−9), by more central memory Treg cells, and by
increased activated central memory cells expressing PD1.
We were able to analyze in more details cells from seven
patients and six controls, measuring the expression of several
chemokine receptors and of molecules that are considered master
regulators (i.e., lineage-specifying transcription factors). Figure 2d
shows a representative comparison of the cytometric analysis
within CD3+CD4+ cells in a control donor (upper panels) and a
COVID-19 patient. The gating strategy for the identification of
CD4+ T cells is reported in Supplementary Fig. 1.
As indicated in Fig. 2e, patients displayed a lower percentage of
cells expressing CCR6 or CXCR3, and of those co-expressing CCR6
and CD161, but higher percentages of CXCR4+ or CCR4+ cells; no
differences were noted in the expression of T-bet or GATA3.
Characterization and count of CD8+ T cell subsets. Figure 3a
shows the manual gating strategy that we used for the identifi-
cation of different types of CD8+ T cells, which was similar to the
strategy used for CD4+ T cells. As shown in Fig. 3b, healthy
donors and COVID-19 patients displayed a comparable percen-
tage of total CD8+ T cells, even if the absolute number was lower
in patients. Both the percentage and absolute number of naïve
and central memory cells were lower in patients, while the per-
centage, but not the absolute number of TE cells was higher.
Figure 3c reports that patients had a higher percentage and
absolute number of activated cells (expressing HLA-DR and
CD38), and higher percentages of cells expressing PD1 and/or
CD57, markers that are associated to cell senescence/exhaustion.
No differences were present as far as stem cell memory cells were
concerned, similarly with what observed among CD4+ T
lymphocytes (not shown).
We then performed the same unsupervised analysis by using
FlowSOM meta-clustering to investigate the phenotype of CD8+
T cells, represented by the UMAP in Fig. 4a and by the heat map
in Fig. 4b. In this case, 13 clusters were identified and analyzed.
As reported in Fig. 4c, showing the statistical analysis of
chemokine receptors and master regulators in patients vs.
controls, COVID-19 patients were characterized by higher
percentages of terminal effector cells expressing CD38 alone or
in combination with CD57, and by activated effector memory
cells expressing PD1 or CD57. They also displayed significantly
lower percentages of naïve and central memory T cells, which
could suggest that patients displayed an exhausted CD8+ T cell
compartment.
Figure 4d shows a representative comparison of the cytometric
analysis of CD3+CD8+ cells in a control donor (upper panels)
and in a COVID-19 patient (lower panels). The gating strategy
for the identification of CD8+ T cells is reported in Supplemen-
tary Fig. 1. We could also identify CD8+ T lymphocytes
expressing high levels of CD161 that, along with CCR6, are
present in most mucosal associated invariant T (MAIT) cells
characterized by Vα7.2 T cell receptor17. Concerning the expres-
sion of chemokine receptors and of transcription factors among
CD8+ T cells, we found that patients expressed lower percentages
of CCR6+, CXCR3+, T-bet+ or CD161high cells, and of CXCR3+
T-bet+ or CCR6+CD161+ lymphocytes (Fig. 4e); they also had
higher percentages of cells expressing CCR4, CXCR4, or GATA3.
T cell proliferation and mitochondrial bioenergetics. Figure 5a,
related to CD4+ cells, shows in the upper panels the gating
strategy for the identification of cells that had undergone either
cell proliferation (giving origin to the so-called “proliferation
index”, PI, revealed by those events in the red rectangles) or that
replicated different times (“percentage divided”, PD, related to the
different fluorescence peaks). A representative example of a
healthy control and a COVID patient is shown. Lower panels
compare five patients and five controls, and show that TE CD4+
T cells from patients had a lower proliferation index. Figure 5b
shows the same analysis applied to CD8+ T cells. In this case,
patients showed both a significantly lower proliferation index and
a higher percentage of dividing cells. The gating strategy for
Fig. 1 Differentiation, activation, and exhaustion of CD4+ T cells. a Gating strategy used to analyze markers related to differentiation, activation status,
senescence, and exhaustion together with identification of Tregs and TSCM within CD4+ T cells. Naïve T cells are identified as CCR7+CD45RA+CD28+
CD27+ cells; TSCM are CCR7+CD45RA+CD28+CD27+CD95+; central memory (CM) are CCR7−CD45RA+CD28+CD27+/−; effector memory (EM)
are CCR7−CD45RA−CD28+/−CD27+/−; terminal effector (TE) are CCR7−CD45RA+CD28−CD27+/−. Activated cells are CD38+HLA-DR+; Treg are
CD127−CD25+; exhausted/senescent are PD1+CD57+. b, c Percentages and absolute numbers of different CD4+ T cell subpopulations in controls (n=
13) and patients (n= 21), obtained by manual gating. Data represent individual values, mean (centre bar) ± SEM (upper and lower bars). Statistical analysis
by two-sided Mann–Whitney nonparametric test; if not indicated, p value is not significant. Source data are provided as a Source Data file.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17292-4
4 NATURE COMMUNICATIONS |         (2020) 11:3434 | https://doi.org/10.1038/s41467-020-17292-4 | www.nature.com/naturecommunications
studying cell proliferation in CD4+ and CD8+ T cells is reported
in Supplementary Fig. 2.
Cellular bioenergetics was studied in CD4+ T cells purified
by magnetic sorting and stimulated overnight or not with anti-
CD3 plus anti-CD28 mAbs. Figure 6a, related to the analysis of
mitochondrial oxygen consumption rate (OCR), shows that
basal respiration, maximal respiration, spare respiratory
capacity (SRC), and the amount of oxygen used for ATP
production were similar in stimulated (S) or non-stimulated
(NS) cells from controls and patients. Figure 6b, related to the
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Fig. 2 Unsupervised analysis of CD4+ T cells and their characterization. a Uniform Manifold Approximation and Projection (UMAP) representation of
the CD4+ T cell landscape. b Heat map representing different CD4+ T cell clusters identified by FlowSOM, with relative identity and percentages in healthy
controls and COVID-19 patients. The colors in the heat map represent the median of the arcsinh, 0–1 transformed marker expression calculated over cells
from all the samples, varying from blue for lower expression to red for higher expression. The dendrogram on the left represents the hierarchical similarity
between the metaclusters (metric: Euclidean distance; linkage: average). Each cluster has a unique color assigned (bar on the left). Barplot along the rows
(clusters) and values on the right indicate the relative sizes of clusters. c Differential analysis between controls (bar color: salmon; n= 13) and COVID-19
(emerald; n= 21). The heat represents arcsine-square-root transformed cell frequencies that were subsequently normalized per cluster (rows) to mean of
zero and standard deviation of one. The color of the heat varies from blue indicating relative under-representation to orange indicating relative over-
representation. Bar and numbers at the right indicate significant differentially abundant clusters (green) and adjusted p values. Clusters are sorted
according to adjusted p values, so that the cluster at the top shows the most significant abundance changes between the two conditions. d Representative
dot plots related to the expression of different chemokine receptors and lineage-specifying transcription factors in gated CD4+ T from a control (upper)
and a patient (lower panel). Numbers indicate the percentage in each quadrant. Two experiments (one for the control group, one for patients) out of 13 are
shown. Numbers indicate the percentage in each quadrant. The gating strategy for the identification of CD4+ T cells is reported in Supplementary Fig. 1.
e Percentages of different CD4+ T cell subpopulations in controls (n= 6) and patients (n= 7), obtained by manual gating. Data represent individual values
(dots), mean (centre bar) ± SEM (upper and lower bars). Statistical analysis is performed by two-sided Mann–Whitney nonparametric test; if not indicated,
p value is not significant. Source data are provided as a Source Data file.
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analysis of ECAR, shows that stimulated (S) or NS cells from
patients and controls had the same capacity to switch from
respiration to glycolysis, and had similar basal and maximal
ECAR.
Detecting cytokine storm in patients’ plasma. We measured
plasma levels of 31 cytokines, chemokines, and immune-related
molecules in 21 patients and 13 healthy controls (Fig. 7). We
found that galectin-1, galectin-3, galectin-9, C-C motif chemokine
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ligand-2 (CCL2, also known as MCP-1), CCL3 (also known as
MIP-1a), CCL4 (also known as MIP-1b), C-X-C motif chemokine
ligand-6 (CXCL6), CD27, CD40, CD40L, TNF, IFN-γ, IL-1α, IL-
1β, IL-4, IL-6, IL-7, IL-8, IL-10, IL-13 major histocompatibility
complex class I chain-related protein A (MICA), glucocorticoid-
induced TNFR-related protein (GITR, also known as receptor
superfamily member 18), and programmed death-ligand 1 (PD-
L1) were significantly higher in COVID-19 patients, as compared
with controls. No statistical differences were found as far as MIP-
2 (also known as CXCL2) was concerned.
Likely due to technical limitations of the multiplex assay,
CCL7, GITR, IL-2, IL-3, and IL-5 were not detected in most
patients and controls. Also due to the fact that levels of IL-12p70,
IL-15, and IL-17 were undetectable in almost all of the healthy
controls, we were unable to perform statistical comparisons, even
although in most patients these cytokines were present at
detectable levels.
In vitro production of proinflammatory cytokines. We studied
six different functions of CD4+ and CD8+ T cells, including the
production of IFN-γ, IL-17, IL-2, TNF and granzyme-B, along
with the expression of the degranulation marker CD107a18.
Figure 8 shows a representative example of the detection of
intracellular cytokines and the presence of CD107a in CD4+
T cells (Fig. 8a) or CD8+ T cell (Fig. 8b) from a healthy donor
(CONTROL, upper quadrants) and a patient (lower quadrants).
The gating strategy for studying intracellular cytokines in CD4+
and CD8+ T cells is reported in Supplementary Fig. 3. As
summarized in (Fig. 8c), in comparison with six controls, a
significantly higher amount of CD4+ T cells from eight COVID-
19 patients was able to produce TNF, CD107a, IFN-γ, IL-2, and
particularly IL-17 (that showed the highest difference). The
production of granzyme-B was similar in the two groups. A
similar trend was present among CD8+ T cells (Fig. 8d), whose
stimulation with anti-CD3/CD28 resulted in significantly higher
production of CD107a, IL-17, and especially IL-2. A trend, even if
not reaching a statistical significance, was present as far as the
production of TNF and IFN-γ is concerned.
We then investigated CD4+ and CD8+ T cell polyfunctionality
by analyzing the simultaneous production of TNF, CD107a, IFN-
γ, IL-2 and IL-17 (Fig. 9). It is to note that in this case we indicate
the percentage of cells exerting one or more functions (consider-
ing the entire set of cells, that is taken as 100%), without
considering the power of the global response19. Based on the use
of five markers, we could discriminate 31 different populations of
CD4+ or CD8+ T cells able to produce one or more molecules;
the population that had no activity, i.e., that was five times
negative for all five markers, was excluded from the analysis.
Figure 9a shows that CD4+ and CD8+ T cells from patients and
controls had very global patterns of polyfunctionality. However,
different functional types of CD4+ T cells producing TNF were
present at higher proportions in patients as compared with
controls (Fig. 9b). Moreover, patients also showed more cells
simultaneously producing IL-2 and IL-17 than controls, con-
firming what was reported above.
Discussion
In this study we describe the main changes in the T cell com-
partment of patients with COVID-19 pneumonia. Most were
lymphopenic, and most did not require noninvasive ventilation,
indicating that at the time of blood collection the disease was
severe, but not too advanced to require intubation and mechan-
ical ventilation. Our data thus indicate that several immune
alterations are present when the infection becomes clinically
relevant. These data are also in agreement with the immunolo-
gical changes recently described in a patient with mild-to-
moderate COVID-19 patient that required hospitalization, and
showed a significant increase in activated T cells20. Studies on
asymptomatic, infected individuals are crucial to better under-
stand the immunopathogenesis of COVID-19.
In COVID-19 patients with pneumonia, we found an increase
capability of CD4+ or CD8+ T cells to produce in vitro IL-17, that
is able to strengthen the inflammation response and to activate
neutrophils. In peripheral blood, patients also showed low per-
centages of both CD4+ and CD8+ T cells expressing CCR6 and
high levels of CD161, which is typical of TH17 and of mucosal
associated invariant T (MAIT) cells, respectively. The loss of cir-
culating CD4+CD161+CCR6+ cells contributes to disease pro-
gression in macaques infected with the simian immunodeficiency
virus, and it has been shown that these cells accumulate in the
rectal mucosa, enhancing inflammation21. In the same infection
model, the percentage of IL-17 producing CD8+CD161+ cells
present in the lung can be fourfold higher than that in peripheral
blood22. Furthermore, cells present in the lung were able to
produce more IL-17 than those from peripheral blood. Taken
together, these findings underline the importance of IL-17 in
COVID-19, and likely could pave the way to novel therapeutic
approaches based upon IL-17 blockage by biological drugs that are
already available.
Very few data exist on the changes in the T cell compartment
in patients affected by SARS-CoV-2 infection. Previous studies
have shown changes in the T cell family, which is characterized
by signs of exhaustion23,24. In most COVID-19 patients the
proportions of T cells subsets can remain within the normal
range, but a decrease can exist in CD4+ and CD8+ T cell counts
or in CD4+/CD8+ ratio25,26. Our data are in agreement with
these observations, but are enhanced by our analyses of dif-
ferent subpopulations of both CD4+ and CD8+ T lymphocytes.
Indeed, whereas on the one hand no gross changes between
patients and controls are detected simply using markers related
to naïve, memory or effector cells, on the other hand our more
sophisticated and detailed analysis reveals significant
differences.
Treg are crucial for regulating immune homeostasis and self‐
tolerance27,28. They express the forkhead box transcription factor
Foxp3, but can also be identified by detecting the high expression
of the IL‐2 receptor α‐chain (CD25) and low/null expression of
IL‐7 receptor α‐chain (CD127)29, along with other surface
molecules such as CD39 and CD7330,31. They suppress auto-
immune phenomena, dampen allergic reactions, or block trans-
plant rejection, but they can also inhibit a protective immune
Fig. 3 Differentiation, activation, and exhaustion of CD8+ T-cell subsets. a Gating strategy used to analyze markers of differentiation, activation status,
senescence, and exhaustion, together with identification of TSCM within CD8+ T cells. Naïve T cells are identified as CCR7+CD45RA+CD28+CD27+;
TSCM are CCR7+CD45RA+CD28+CD27+CD95+; central memory (CM) are CCR7−CD45RA+CD28+CD27+/−, effector memory (EM) CCR7−CD45RA−
CD28+/−CD27+/−; terminal effector (TE) are CCR7−CD45RA+CD28−CD27+/−. Activated cells are CD38+HLA-DR+; exhausted/senescent are PD1+
CD57+. b, c Percentages and absolute numbers of different CD8+ T cell subpopulations in controls (n= 13) and patients (n= 21), obtained by manual
gating. Data represent individual values, mean (centre bar) ± SEM (upper and lower bars). Statistical analysis by two-sided Mann–Whitney nonparametric
test; if not indicated, p value is not significant. Source data are provided as a Source Data file.
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Fig. 4 Unsupervised analysis of CD8+ T cells and their characterization. a Uniform Manifold Approximation and Projection (UMAP) UMAP
representation of CD8+ T cell landscape. b Heat map representing different clusters identified by FlowSOM, with relative identity and percentages in
controls and patients. The color in the heat map represents the median of the arcsinh, 0–1 transformed marker expression calculated over cells from all the
samples, varying from blue for lower expression to red for higher expression. The dendrogram on the left represents the hierarchical similarity between the
metaclusters (metric: Euclidean distance; linkage: average). Each cluster has a unique color assigned (bar on the left). Barplots along the rows (clusters)
and values on the right indicate the relative sizes of clusters. c Differential analysis between CTR (bar color: salmon; n= 13) and COVID-19 (emerald; n=
19). The heat represents arcsine-square-root transformed cell frequencies that were subsequently normalized per cluster (rows) to mean of zero and
standard deviation of one. The color of the heat varies from blue indicating relative under-representation to orange indicating relative over-representation.
Bar and numbers at the right indicate significant differentially abundant clusters (green) and adjusted p values. Clusters are sorted according to adjusted p
values, so that the cluster at the top shows the most significant abundance changes between the two conditions. d Representative dot plots related to the
expression of different chemokine receptors and lineage-specifying transcription factors in gated CD8+ T from a control donor (upper) and a patient (lower
panel). Two experiments (one for the control group, one for patients) out of 13 are shown. Numbers indicate the percentage in each quadrant. The gating
strategy for the identification of CD8+ T cells is reported in Supplementary Fig. 1. e Percentages of different CD8+ T cell subpopulations in controls (n= 6)
and patients (n= 7), obtained by manual gating. Data represent individual values (dots), mean (centre bar) ± SEM (upper and lower bars). Statistical
analysis is performed by two-sided Mann–Whitney nonparametric test; if not indicated, p value is not significant. Source data are provided as a Source
Data file.
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response against invading pathogens or tumors32. Here we show
that the percentages of different types of Tregs are increased in
peripheral blood from COVID-19 patients, and that their plasma
contains high amounts of the inhibitory cytokine IL-10.
Patients with COVID-19 had increased amounts of CD8+
T cells expressing CD57, which is considered a key marker of
in vitro replicative senescence and is associated either to human
aging or prolonged chronic infections33. CD57 has been used to
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Fig. 5 Cell proliferation of CD4+ and CD8+ T lymphocytes. a Upper two rows: representative dot plots related to cell proliferation in different types of
CD4+ T cells from a control donor (upper panel) and a patient (COVID, lower panel). Lower two rows indicate the proliferation index and the percentage of
divided cells in all CD4+ T cells, or in naive, central memory (CM), effector memory (EM), or terminally differentiated (TE) cells. Data represent individual
values (dots) from five patients and five controls, mean (centre bar) ± SEM (upper and lower bars). Statistical analysis is performed by two-sided
Mann–Whitney nonparametric test; if not indicated, p value is not significant. The gating strategy for the identification of CD4+ T cells is reported in
Supplementary Fig. 2. b Upper two rows: representative dot plots related to cell proliferation in different types of CD8+ T cells from a control donor (CTR,
upper) and a patient (COVID, lower panel). Lower two rows indicate the proliferation index and the percentage of divided cells in all CD8+ T cells, or in
naive, central memory (CM), effector memory (EM), or terminally differentiated (TE) cells. Data represent individual values (dots) from five patients and
five controls, mean (centre bar) ± SEM (upper and lower bars). Statistical analysis is performed by two-sided Mann–Whitney nonparametric test; if not
indicated, p value is not significant. The gating strategy for the identification of CD8+ T cells is reported in Supplementary Fig. 2.
Fig. 6 Mitochondria bioenergetics of CD4+ T cells. a Representative traces (out of 12 experiments) of oxygen consumption rate (OCR) of unstimulated
(NS) and stimulated (S) CD4+ T cells from healthy controls (CTR; n= 7) and COVID patients (n= 5). OCR was measured in real time, under basal
condition and in response to indicated mitochondria inhibitors: oligomycin (Oligo, 2 μM), cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP, 0.5 μM),
and antimycin A plus rotenone (Rot/AA, 0.5 μM). Histograms show the quantification of basal respiration, maximal respiration, spare respiratory capacity
(SRC), ATP-linked respiration (ATP), percentage of SRC, and area under the curve (AUC) in cell stimulated (S) with anti-CD3/28 or non-stimulated (NS)
from controls and patients. The percentage of SRC represents the ratio between the seventh and the third measurement. AUC was obtained by analyzing
the area under the curve from the sixth to the eleventh measurement. Data represent individual values (dots) from seven patients and five controls, mean
(centre bar) ± SEM (upper and lower bars). Statistical analysis by two-sided Mann–Whitney nonparametric test shows no statistical differences between
controls and patients. b Representative traces (out of 12 experiments) of extracellular acidification rates (ECAR) of unstimulated (NS) and stimulated (S)
CD4+ T cells from one healthy control (CTR) and one COVID patient. ECAR was measured under basal conditions and in response to FCCP. Data
represent individual values from seven controls and five patients, mean (centre bar) ± SEM (upper and lower bars) concerning the quantification of basal
ECAR and maximal ECAR in cell stimulated (S) with anti-CD3/28 or non-stimulated (NS) from controls and patients. Statistical analysis by two-sided
Mann–Whitney nonparametric test shows no statistical differences between controls and patients.
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detect functional immune deficiency in patients with auto-
immune diseases, infectious diseases, and cancers. It has been
suggested that CD57+ cells display a high susceptibility to
activation‐induced cell death, and are not able to undergo cell
proliferation despite their preserved ability to secrete cytokines
after activation34. We have found a decreased proliferation
index among TE CD4+ and CD8+ T lymphocytes from
COVID-19 patients. T cells show phenotypic features of an
exhausted state including the upregulated expression of the
inhibitory receptors such as PD1. T cell exhaustion is
Fig. 7 Plasma level of cytokines and chemokines from COVID-19 patients and controls. Quantification of cytokines and other mediators in plasma
obtained from COVID-19 patients (n= 23) and healthy controls (n= 15). Data represent individual values, mean (centre bar) ± SEM (upper and lower
bars). Statistical analysis by two-sided Mann–Whitney nonparametric test; if not indicated, p value is not significant. Source data are provided as a Source
Data file.
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characterized by functional unresponsiveness, which prevents
massive immunoactivation and associated autoimmune tissue
damage. Thus, it could be possible that in COVID-19 patients
the activation of these cells is followed not only by the lack of
clonal expansion (as revealed by the decreased proliferation)
but also by the production of molecules that cause
inflammation.
Furthermore, we have observed that cells from patients dis-
played higher percentages of different cell types expressing of
PD1, a crucial molecule for the induction and maintenance of
peripheral tolerance, and for maintaining T cells stability and
integrity35. The PD1/PD-L1 axis also mediates potent inhibitory
signals to block proliferation and function of T effector cells,
causing inimical effects on antiviral immunity. We have found
significantly high plasma levels of PD-L1 in our patients, and
studies are needed to understand whether and how the infection
uses this pathway for inhibition of an efficient antiviral immune
response.
Fig. 8 Cytokine production by CD4+ and CD8+ T cells after in vitro stimulation with anti-CD3/28. a Representative dot plots (out of 18 experiments)
related to the intracellular cytokine staining of CD4+ T cells of a control donor (upper panels) and a COVID patient (lower panels) after in vitro stimulation
with anti-CD3/CD28. The gating strategy for the identification of CD4+ T cells is reported in Supplementary Fig. 3. b Representative dot plots (out of 18
experiments) related to the intracellular cytokine staining of CD8+ T cells of a control donor (upper panels) and a COVID patient (lower panels) after
in vitro stimulation with anti-CD3/CD28. The gating strategy for the identification of CD8+ T cells is reported in Supplementary Fig. 3. c Comparison
between the total production of IFN-γ, TNF, IL-17, IL-2, CD107a and granzyme-B by CD4+ T cells after in vitro stimulation with anti-CD3/CD28. Data
represent individual values from six controls and eight patients, mean (centre bar) ± SEM (upper and lower bars). Statistical analysis by two-sided
Mann–Whitney nonparametric test; if not indicated, p value is not significant. d Comparison between the total production of IFN-γ, TNF, IL-17, IL-2, CD107a
and granzyme-B by CD8+ T cells after in vitro stimulation with anti-CD3/CD28. Data represent individual values from six controls and eight patients, mean
(centre bar) ± SEM (upper and lower bars). Statistical analysis by two-sided Mann–Whitney nonparametric test; if not indicated, p value is not significant.
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An excessive inflammatory response evidenced by elevated
levels of proinflammatory cytokines and chemokines has been
described in patients affected by the SARS-CoV epidemic in
200336,37. Moreover, in vitro experiments revealed that several
different cell types from those patients were able to produce high
amounts of cytokines38,39. High plasma levels of proinflammatory
molecules indicating a TH1/TH17 response were also reported in
patients with MERS-CoV infection, with increased concentrations
Fig. 9 Polyfunctionality of CD4+ and CD8+ T cells after in vitro stimulation with anti-CD3/28. a Pie charts representing the proportion of responding
CD4+ (upper pies) and CD8+ (lower pies) T cells producing different combinations of CD107a, IL-2, IFN-γ, and TNF after anti-CD3/CD28 stimulation in
control donors (left; n= 7) and patients (right; n= 11). Frequencies were corrected by background subtraction as determined in non-stimulated controls
using SPICE software. Pie arches represent the total production of different cytokines. b Comparison between the production of different combinations of
cytokines by CD4+ T cells after in vitro stimulation with anti-CD3/CD28. Data represent individual values from 7 controls and 11 patients, mean (centre
bar) ± SEM (upper and lower bars). Statistical analysis by two-sided Mann–Whitney nonparametric test; if not indicated, p value is not significant.
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of IFN-γ, TNF, IL-15, and IL-1740. Similar data, along with
skewed in vitro cytokine production by T cells, have been
described in patients infected by MERS coronavirus41. In our
COVID-19 patients, plasma concentrations of many proin-
flammatory cytokines and chemokines were dramatically
increased, which is in accordance to all the aforementioned
reports describing the so-called “cytokine storm”42.
The effects of the presence of high amounts of molecules that
are produced by several cell types and act on innate immune cells
must be considered. Amongst these molecules, IL-8 might be of a
particular importance, since it recruits neutrophils from the blood
to infected or injured tissue. IL-8 production can be induced by a
wide range of stimuli, including TNF, IL-1, bacteria, viruses, and
cellular stress, and it can be synthesized by several cell types,
including monocytes, macrophages, endothelial and epithelial
cells, fibroblasts, T lymphocytes, hepatocytes, synovial cells, and
keratinocytes43. Its receptors, CXCR1 and CXCR2, are expressed
on neutrophils, monocytes, CD8+ T and NK cells, mast cells,
basophils, and myeloid-derived suppressor cells. In neutrophils,
receptor activation stimulates degranulation and the production
of reactive oxygen species44. When a respiratory virus, such as
SARS-CoV-2, enters alveoli, it first encounters and infects
alveolar epithelial cells, which can then produce IL-8 that in turn
attracts and activates neutrophils and macrophages. These start
damaging the organ, eventually triggering a much more complex
series of pathogenic events, including, amongst others, endothe-
lial damage, platelet activation, and intravascular thrombosis.
Although it was not possible to precisely determine the site of IL-
8 production, even for our patients with pneumonia, it is rea-
sonable to hypothesize that alveolar cells are intimately involved
in this phenomenon.
Surprisingly, we also observed a marked plasma increase of
typical TH2 cytokines, including IL-4, IL-10, and IL-13. This
could indicate that the activation of immune system is really
massive, indiscriminately involving all cells, and, similarly to what
occurs during bacterial sepsis, could cause a form of immune
paralysis45.
Galectin-1, galectin-3, and galectin-9 were increased in patients
as compared with controls. Galectins represent a family of soluble
β-galactoside-binding proteins widely expressed at sites of
inflammation and infection that have emerged as a new class of
damage-associated molecular patterns (DAMPs) or resolution-
associated molecular patterns, serving to magnify or to otherwise
correct inflammatory responses46,47. In particular, galectin-1 acts
typically as a proresolving mediator by repressing a number of
innate and adaptive immune programs. Conversely, galectin-3
and -9 have been proposed to act as alarmins (or DAMPs) that
amplify inflammatory responses during sepsis and several types
of infection. To our knowledge, these are the first data describing
the presence of these types of soluble mediators in patients with
COVID-19, and further studies are needed to investigate their
importance in the immunopathogenesis of the disease, or their
possible consideration as potential therapeutic targets.
The massive production and release of cytokines is very similar
to what occurs during polyclonal, superantigen-driven, T-cell
activation48. A fourfold increase of the levels of a TH1 molecule
such as IFN-γ was indeed observed in plasma from COVID-19
patients as compared with controls. IFN-γ activates macrophages,
which produce proinflammatory cytokines, which then over-
whelm the system. When cells from patients were stimulated with
anti-CD3/28, an increased number of CD4+ T cells producing
IFN-γ, TNF, IL-17, and IL-2 was observed as compared with
healthy controls. This indicates that T cells from COVID-19
patients have a higher ability over controls to respond in vitro to
stimulatory challenges producing potentially dangerous mole-
cules. Studies are underway to investigate the functional
phenotype of specific T cells, i.e., those responding to peptide
antigens derived from SARS-CoV-2.
Elevated levels of serum proinflammatory cytokines and che-
mokines are known to contribute, as a cytokine storm, to the
increased severity of disease caused by some strains of corona
virus. Unique immunoregulatory system mediated by T cell
exhaustion and suppressive cytokines such as IL-10 are respon-
sible for limiting excessive inflammation and play an important
role in homeostasis in the lungs. A balance in the levels of
immunoactivation and immunosuppression may therefore be
crucial in host defense against highly pathogenic corona virus
infection.
We are well aware of the limitations of our study. First of all,
the fact that the relatively low number of patients, who were
however chosen on the basis of similar clinical characteristics,
does not allow us to divide them into those with a mild or severe
course of the infection, having sufficient statistical power for
further analyses. Second, due to fact that the study started when
there was no treatment at all, and that in the days following blood
collection some patients would have been treated and others not,
it is difficult to understand which immune modifications can be
considered predictive markers of the natural containment of the
infection, or of the success of the therapy. Third, for this study we
could not provide longitudinal data, but just compared the cohort
with healthy donors. However, in COVID-19 patients with
pneumonia, we have found the presence of: (i) increased markers
of T cell exhaustions, activation, and senescence; (ii) an altered
differentiation of different T cell subtypes; (iii) high plasma levels
of a variety of cytokines, from those with proinflammatory action
to those that are able to inhibit the immune response, from those
that indicate a skewing towards TH1 to those that reveal a
skewing towards TH2; (iv) massive in vitro production of several
cytokines, with a potential skewing of activated cells towards
TH17 phenotype; and (v) decrease of those circulating cells that
are known to localize in the lung and other tissues, and recruit
neutrophils.
In conclusion, in COVID-19 patients, concomitant aspects of
immune inhibition, activation, exhaustion, and complex altera-
tions within cells at different stage of differentiation exist, and a
huge variety of cytokines are produced and released. The overall
picture that emerges underlines the ability of SARS-CoV-2 to
provoke, in a very short period of time but, fortunately, not in all
infected individuals, a massive activation of immune responses.
However, and thanks to the considerable efforts that the scientific
community is devoting to studies of the immunopathogenesis of
COVID-19, the progression of the viral infection starts to show
some weak points that may be therapeutically relevant. For
example, a therapeutic approach now exists based on the
administration of drugs that block IL-6 pathway, and is now
significantly ameliorating the course of the disease13,49. IL-17 is
crucial in recruiting and activating neutrophils, cells that can
migrate to the lung and are heavily involved in the pathogenesis
of COVID-19. We show here that a significant skewing of T cell
activation towards TH17 functional phenotype exists in COVID-
19 patients, and we therefore suggest that blocking IL-17 pathway
by biological drugs that are already available and used to treat
different pathologies could be a novel, additional strategy to treat
patients infected by SARS-CoV-2.
Methods
Study design. This is a case-control, cross sectional, single-centre study, approved
by the local Ethical Committee (Comitato Etico dell’Area Vasta Emilia Nord,
protocol number 177/2020, March 11th, 2020) and by the University Hospital
Committee (Direzione Sanitaria dell’Azienda Ospedaliero-Universitaria di Mod-
ena, protocol number 7531, March 11th, 2020). Each participant, including healthy
controls, provided informed consent according to Helsinki Declaration, and all
uses of human material have been approved by the same Committees. A total of 39
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COVID-19 patients were included in the study; they had a median age of 64 years
(range 35–94), 7 were females, 32 males. Patients were matched for age and gender
with a total of 25 healthy donors (CTR), median age 60 years (range 33–66 years).
We recorded demographic data, medical history, symptoms, signs, temperature,
and main laboratory findings from each patient. Data were coded and recorded in
Excel 14.1.0 for Mac in a database present in the Infectious Disease Clinics and
routinely used. The total number and type of leukocytes in peripheral blood was
analyzed by hemocytometer in the Clinical Laboratory of the University Hospital,
according to routine methods.
Blood collection and isolation of mononuclear cells. Up to 20 mL of blood were
collected from each patient in vacuettes containing ethylenediamine-tetraacetic
acid. Blood was immediately processed. Isolation of peripheral blood mononuclear
cells (PBMC) was performed using ficoll-hypaque according to standard proce-
dures50. PBMC were then stored in different aliquots at the concentration of 5–10
millions/mL in liquid nitrogen in fetal bovine serum supplemented with 10%
dimethyl sulfoxide. Plasma was then collected, centrifuged twice, and stored at
−80 °C until use. Measurements were taken from individual patients; in the case of
plasma, each measurement was performed in duplicate and only the mean was
considered and shown.
T cell immunophenotype by polychromatic flow cytometry. Thawed PBMC
were washed twice with RPMI 1640 supplemented with 10% fetal bovine serum
and 1% each of l-glutamine, sodium pyruvate, nonessential amino acids, anti-
biotics, 0.1 M HEPES, 55 μM β-mercaptoethanol and 0.02 mg/ml DNAse51.
For the detailed analysis of T cell phenotype, PBMC were counted and up to 1
million PBMC were stained with the Duraclone IM T cell panel (from Beckman
Coulter, Miami, FL) added with another five fluorescent mAbs and a marker of cell
viability. Along with side and forward scatter signals, signals were obtained from
different fluorochrome-labeled mAbs, i.e., CD45 conjugated with Krome Orange,
CD3 APC-A750, CD4 APC, CD8 AF700, CD27 PC7, CD57 Pacific Blue, CD279
(PD1) PC5.5, CD28 ECD, CCR7 PE, CD45RA FITC, HLA-DR BUV661, CD127
BV650, CD25 BV785, CD95 BUV395, CD38 BUV496, and PromoFluor-840
(Promokine, PromoCell, Heidelberg, Germany). A minimum of 500,000 cells per
sample were acquired on a CytoFLEX LX flow cytometer (Beckman Coulter)18.
For the analysis of T cell skewing toward TH1, TH2, or TH17, and chemokine
receptor expression, thawed PBMC were washed twice with PBS and stained with
the viability marker AQUA LIVE DEAD (ThermoFisher). Then, up to 1 million
cells were washed and stained at 37 °C with the following mAbs: anti-CXCR3-
AF488, -CXCR4-PE. Cells were washed again and stained at room temperature
with anti-CD161-PC7, -CCR6-BV605, -CCR4-PE-CF594, -CD4-AF700, -CD8-
APC-Cy7. Cells were washed, fixed, and permeabilized using Foxp3/Transcription
Factor Staining Buffer Set (ThermoFisher). Finally, cells were stained with anti-
GATA3-BV421 and anti-TBET-APC, and washed. A minimum of 500,000 PBMC
were acquired by using Attune NxT acoustic focusing flow cytometer
(ThermoFisher).
Supplementary Table 5 shows all the clones and monoclonal antibodies used in
this study.
Representation of high parameter flow cytometry. Flow Cytometry Standard
(FCS) 3.0 files were imported into FlowJo software version 9 (Becton Dickinson,
San Josè, CA), and analyzed by standard gating to eliminate aggregates and dead
cells, and to identify CD3+CD4+ T cells and CD8+ T cells. Then, data from 5000
CD4+ T cells and 2500 CD8+ T cells per sample were exported for further analysis
in R, by following a script that makes use of Bioconductor libraries and R statistical
packages (CATALYST 1.10.1). The script is available at: https://github.com/
HelenaLC/CATALYST)52. The selection of cofactor for data transformation was
checked on Cytobank premium version (see: cytobank.org). The platform Flow-
SOM (available at: https://bioconductor.org/packages/release/bioc/html/FlowSOM.
html) was used to perform the metaclustering (K= 20). Data were subsequently
displayed using the dimensionality reduction method named UMAP2.
Quantification of cytokine plasma levels. The plasma levels of 31 molecular
species was quantified using a Luminex platform (Human Cytokine Discovery,
R&D System, Minneapolis, MN) for the simultaneous detection of the following
molecules: IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-
13, IL-15, IL-17, galectin-1, galectin-3, galectin-9, IFN-γ, TNF, GITR, PD-L1,
MICA, CCL-2, CCL-3, CCL-4, CCL-7, CXCL6, MIP-2, sCD27, sCD40, sCD40L,
according to the manufacturer’s instruction. Data in the scatter plots represent the
mean of two technical replicates.
In vitro stimulation and intracellular cytokine staining. For functional assays on
cytokine production by T cells, thawed isolated PBMCs were stimulated for 16 h at
37 °C in a 5% CO2 atmosphere with anti-CD3/CD28 (1 μg/mL) in complete culture
medium (RPMI 1640 supplemented with 10% fetal bovine serum and 1% each of l-
glutamine, sodium pyruvate, nonessential amino acids, antibiotics, 0.1 M HEPES,
55 μM β-mercaptoethanol). For each sample, at least 2 million cells were left
unstimulated as negative control, and 2 million cells were stimulated. All samples
were incubated with a protein transport inhibitor containing brefeldin A (Golgi
Plug, Becton Dickinson) and previously titrated concentration of CD107a-PE.
After stimulation, cells were stained with LIVE-DEAD Aqua (ThermoFisher Sci-
entific) and surface mAbs recognizing CD3 PE- Cy5, CD4 AF700, and CD8 APC-
Cy7 (Biolegend, San Diego, CA, USA). Cells were washed with stain buffer, and
fixed and permeabilized with the cytofix/cytoperm buffer set (Becton Dickinson)
for cytokine detection. Cells were next stained with previously titrated mAbs
recognizing IL-17 BV421, TNF BV605, IFN-γ FITC, IL-2 APC, or granzyme-B
BV421 (all mAbs from Biolegend). Then, a minimum of 100,000 cells per sample
were acquired on a Attune NxT acoustic cytometer (ThermoFisher).
Proliferation assay. Cells from five patients and five controls were stimulated for
6 days in resting conditions, or after stimulation with anti-CD3 plus anti-CD28
mAbs (1 μg/mL each, Miltenyi Biotech, Bergisch Gladbach, Germany) and with 20
ng/mL IL-2. The fluorescent dye 5,6-carboxyfluorescein diacetate succinimidyl
ester was used at a concentration of 1 μg/mL (TechnoFisher) according to standard
procedures. Flow cytometric analyses for the identification of cycling cells
belonging to different T cell populations were performed by gating TN, TCM,
TEM, TE among CD4+ and CD8+ T cells16.
Mitochondrial bioenergetics and metabolic assays. Due to lack of cells, we
could only purify and study CD4+ T cells in five patients, compared with five
controls. CD4+ T cells were first sorted using magnetic antibodies (Miltenyi Bio-
tech), according to the manufacturer’s instructions, seeded in triplicate at con-
centration of minimum 3.5 × 105 cells/well, rested for 4 h and stimulated for 16 h
with anti-CD3 plus anti-CD28 as indicated above. Real-time measurement of OCR
and ECAR was performed on a XFe-96 Seahorse Extracellular Flux Analyzer
(Agilent, Santa Clara, CA, USA) using the MitoStress kit, according to manu-
facturer’s procedures. OCR was measured in XF media (non-buffered DMEM
medium, containing 10 mM glucose, 2 mM L-glutamine, and 1 mM sodium pyr-
uvate), under basal conditions and in response to 2 μM oligomycin, 0.5 μM of
carbonylcyanide- 4-(trifluoromethoxy)-phenylhydrazone (FCCP) and 0.5 μM of
antimycin and rotenone (all from Sigma Aldrich). Indices of mitochondrial
respiratory function were calculated from OCR profile: basal OCR (before addition
of oligomycin), ATP-linked OCR (calculated as the difference between basal OCR
rate and oligomycin-induced OCR rate), and maximal OCR (calculated as the
difference of FCCP rate and antimycin plus rotenone rate)53. Basal and maximal
ECAR values were also measured. OCR and ECAR values were normalized to the
number of cells per well.
Statistical analysis. High-dimensional cytometric analysis was performed by
using differential discovery in high-dimensional cytometry via high-resolution
clustering54. Quantitative variables were compared using Mann–Whitney test.
Simplified Presentation of Incredibly Complex Evaluation (SPICE) software (ver-
sion 6, kindly provided by Dr. Mario Roederer, Vaccine Research Center, NIAID,
NIH, Bethesda, MD, USA) was used to analyze flow cytometry data on T cell
polyfunctionality17. Data are represented as individual values, means, and standard
errors of the mean. Statistical analyses were performed using Prism 6.0 (GraphPad
Software Inc., La Jolla, USA).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1–9 are provided as a Source Data file. Original.fcs files
concerning cytofluorimetric analysis (Figs. 1–4) are deposited at the flowrepository.org55
in the following folders: T cell characterization: https://flowrepository.org/id/FR-FCM-
Z2N5; T cell phenotype: https://flowrepository.org/id/FR-FCM-Z2N4. Source data are
provided with this paper.
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